Table 1. Summary of Cost ($) and Outcome Results in base-case analysis.
| Strategy | Cost | Progression-free LYs | Overall LYs | QALYs | Incremental cost per QALY* | Comments |
|---|---|---|---|---|---|---|
| PC (control strategy) | 22,127 | 0.206 | 1.058 | 0.513 | NA | |
| Pemetrexed maintenance strategy | 31,646 | 0.300 | 1.208 | 0.604 | 104,657 | Dominated |
| Gefitinib strategy | 24,137 | 0.279 | 1.165 | 0.584 | 28,485 | Dominated |
| Icotinib strategy | 23,989 | 0.303 | 1.202 | 0.607 | 19,809 | Dominance |
| Gefitinib strategy with PAP | 23,721 | 0.279 | 1.165 | 0.584 | 22,577 | Dominated |
| Icotinib strategy with PAP | 23,580 | 0.303 | 1.202 | 0.607 | 15,451 | Dominance |
* Comparing with Control strategy